Neoadjuvant vs. Adjuvant Therapy: What You Need to Know About Sequencing Cancer Treatments

When someone is diagnosed with early-stage lung or breast cancer, one of the first big decisions their care team faces is: Should treatment happen before surgery or after? This isn’t just a technical question-it affects how much treatment you get, how long you wait for surgery, and even whether the treatment actually works for your body. Two main approaches exist: neoadjuvant therapy (before surgery) and adjuvant therapy (after surgery). Both aim to kill cancer cells, but they do it in very different ways-and the choice can change your outcome.

What Neoadjuvant Therapy Really Does

Neoadjuvant therapy means giving drugs-like chemotherapy, immunotherapy, or targeted therapy-before the surgeon cuts into you. The idea isn’t just to shrink the tumor. It’s to see how your cancer reacts in real time. If the tumor shrinks dramatically or disappears entirely on scans, that’s a good sign. But even better: when pathologists examine the tissue removed during surgery and find no live cancer cells, that’s called a pathologic complete response, or pCR. This isn’t just a nice-to-have. In triple-negative breast cancer, patients who hit pCR have a 60-70% lower risk of recurrence compared to those who still have cancer left behind.

In non-small cell lung cancer (NSCLC), the CheckMate 816 trial showed something groundbreaking: when patients got nivolumab (an immunotherapy drug) plus chemo before surgery, 24% achieved pCR. That’s compared to just 2.2% with chemo alone. Those who had pCR didn’t just look better on scans-they lived longer. Median event-free survival jumped from 20.8 months to 31.6 months. That’s over a year longer without the cancer coming back.

Another big advantage? Neoadjuvant therapy lets doctors test drugs on the real tumor inside your body. If the cancer doesn’t respond, you avoid surgery that might not help-and you can switch treatments faster. You’re not guessing anymore. You’re seeing.

What Adjuvant Therapy Is For

Adjuvant therapy comes after surgery. The goal here is simple: clean up whatever cancer cells were left behind. Even if the surgeon removed every visible tumor, tiny clusters of cancer can hide in other parts of your body. These are called micrometastases. Adjuvant therapy is meant to find and kill them.

For decades, this was the standard. After removing a breast tumor or part of a lung, patients got chemo or hormone therapy for 4-6 months. It worked. But it was a shot in the dark. You never knew if the drugs were doing anything-because you couldn’t see the cancer anymore. You were treating based on risk, not response.

Adjuvant therapy still has its place. If your tumor didn’t shrink during neoadjuvant treatment-if you didn’t get pCR-then adjuvant therapy becomes critical. It’s your second chance. And for some cancers, like early-stage hormone receptor-positive breast cancer, it’s still the main path.

Why Sequencing Matters More Than Ever

Here’s where things get tricky. For years, doctors assumed combining neoadjuvant and adjuvant therapy-giving drugs before and after surgery-was the best strategy. But new data says otherwise.

A major 2024 meta-analysis of over 3,200 patients across four key trials (KEYNOTE-671, Neotorch, AEGEAN, NADIM II) found something surprising: adding adjuvant immunotherapy after neoadjuvant treatment didn’t improve survival. Not even a little. The hazard ratio for event-free survival was 0.88-meaning a tiny 12% reduction in risk. That’s not statistically meaningful. Meanwhile, side effects spiked. Nearly 30% of patients on the combo had serious side effects (grade 3 or higher), compared to under 18% with neoadjuvant-only.

Dr. Mark Awad from Dana-Farber put it plainly: “The neoadjuvant-only approach may represent the optimal sequencing strategy for early-stage NSCLC.” Why? Because you get the benefit of early treatment, real-time feedback, and tumor shrinkage-without the extra toxicity of more drugs after surgery.

In breast cancer, the story is similar. A 2023 analysis of over 1,000 patients with early-stage triple-negative breast cancer found no significant difference in survival between those who got neoadjuvant therapy and those who got adjuvant therapy. But here’s the twist: the patients who got neoadjuvant therapy and achieved pCR had much better outcomes than those who didn’t. That’s the real power of neoadjuvant-it doesn’t just treat. It tells you.

Who Gets Which Approach?

Not every patient gets the same treatment. It depends on cancer type, stage, and biology.

• Non-small cell lung cancer (NSCLC): If you have stage IB (tumor ≥4 cm) to IIIA, the NCCN guidelines now recommend neoadjuvant chemoimmunotherapy. This is especially true if your tumor expresses PD-L1 (even 1% or more). The FDA approved nivolumab plus chemo for this use in 2022.
• Triple-negative breast cancer (TNBC): About 45% of patients now get neoadjuvant chemo. Why? Because pCR rates are high-30-40%-and those who hit it have a much better shot at long-term survival.
• HER2-positive breast cancer: Neoadjuvant therapy is standard. Drugs like trastuzumab and pertuzumab are often added to chemo before surgery. pCR here can be over 60%.
• Hormone receptor-positive breast cancer: Still mostly treated with adjuvant therapy. But if the tumor is large or high-risk, neoadjuvant therapy is being used more often to shrink it down.

The bottom line? Neoadjuvant isn’t just for aggressive cancers anymore. It’s becoming the default for anyone who might benefit from seeing how their body responds.

The Hidden Cost of Waiting

One common fear: “If I wait for neoadjuvant therapy, will my cancer spread while I’m waiting?” It’s a real concern. About 5-10% of NSCLC patients experience disease progression during the 9-12 weeks of pre-surgery treatment. And 10-15% of patients can’t have surgery on time because of side effects like low white blood cell counts or lung inflammation.

That’s why timing matters. The ideal window between the last dose of neoadjuvant therapy and surgery is 3-6 weeks. Too soon, and your body hasn’t recovered. Too late, and the tumor might start growing again. This requires tight coordination between medical oncologists, surgeons, and radiologists.

And here’s the catch: only 58% of community hospitals have formal neoadjuvant pathways. Academic centers? 92%. If you’re in a smaller town, getting this sequencing right might mean traveling farther or waiting longer for a multidisciplinary team to review your case.

What’s Next? The Future of Sequencing

The field is moving fast. Trials like KEYNOTE-867 and NeoADAURA are testing whether we can skip adjuvant therapy entirely for patients who respond well. Another big frontier? Circulating tumor DNA (ctDNA).

Imagine this: after neoadjuvant therapy, your doctor takes a blood test to see if any cancer DNA is still floating in your bloodstream. If yes-that’s a red flag. You need more treatment. If no? You might be able to skip adjuvant therapy altogether. Twelve trials are already testing this approach. If it works, it could cut unnecessary treatment for thousands.

Dr. Roy Herbst predicts that within five years, biomarker-driven neoadjuvant therapy will become standard for 70% of early-stage NSCLC cases. Adjuvant therapy will shift from a routine step to a targeted rescue for those who didn’t respond.

And the numbers back it up. The global neoadjuvant therapy market is projected to hit $29.3 billion by 2028. Adoption in the U.S. has doubled in just three years-35% of NSCLC patients now get it before surgery, up from 15% in 2020.

What Should You Do?

If you’re facing surgery for early-stage cancer, ask these questions:

1. Has my cancer type been shown to respond to neoadjuvant therapy?
2. What’s my chance of achieving pCR?
3. Will I get a biopsy or scan after treatment to see if it worked?
4. What happens if I don’t respond?
5. Is there a plan to test for ctDNA after surgery?

Don’t assume adjuvant therapy is the default. Neoadjuvant therapy isn’t experimental anymore-it’s evidence-based. And for many, it’s the smarter path.

Sequencing cancer treatment isn’t about doing more. It’s about doing the right thing at the right time. Neoadjuvant therapy isn’t just a step before surgery-it’s a diagnostic tool, a predictor, and a powerful way to personalize your care. The future of cancer treatment isn’t just about what drugs you get. It’s about when you get them-and why.